Virtus Investment Advisers LLC Sells 5,368 Shares of Stoke Therapeutics, Inc. $STOK

Virtus Investment Advisers LLC lowered its stake in Stoke Therapeutics, Inc. (NASDAQ:STOK) by 40.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 7,955 shares of the company’s stock after selling 5,368 shares during the period. Virtus Investment Advisers LLC’s holdings in Stoke Therapeutics were worth $90,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. AlphaQuest LLC purchased a new stake in Stoke Therapeutics in the first quarter worth about $72,000. US Bancorp DE raised its position in shares of Stoke Therapeutics by 9,743.9% in the 1st quarter. US Bancorp DE now owns 11,222 shares of the company’s stock worth $75,000 after acquiring an additional 11,108 shares in the last quarter. Fox Run Management L.L.C. bought a new position in shares of Stoke Therapeutics in the 1st quarter worth approximately $92,000. Russell Investments Group Ltd. purchased a new position in shares of Stoke Therapeutics in the 1st quarter valued at approximately $107,000. Finally, Police & Firemen s Retirement System of New Jersey boosted its position in shares of Stoke Therapeutics by 33.2% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 9,558 shares of the company’s stock valued at $108,000 after purchasing an additional 2,384 shares in the last quarter.

Stoke Therapeutics Trading Down 1.0%

Shares of STOK opened at $30.89 on Monday. The company has a market cap of $1.76 billion, a price-to-earnings ratio of 46.10 and a beta of 1.14. The business’s fifty day simple moving average is $28.29 and its two-hundred day simple moving average is $19.24. Stoke Therapeutics, Inc. has a 12 month low of $5.35 and a 12 month high of $38.69.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.11). Stoke Therapeutics had a net margin of 19.73% and a return on equity of 13.28%. The business had revenue of $10.63 million for the quarter, compared to analysts’ expectations of $6.06 million. As a group, research analysts forecast that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Insider Activity at Stoke Therapeutics

In other news, General Counsel Jonathan Allan sold 10,000 shares of Stoke Therapeutics stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $25.07, for a total value of $250,700.00. Following the completion of the sale, the general counsel directly owned 11,831 shares in the company, valued at $296,603.17. The trade was a 45.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Edward M. Md Kaye sold 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 8th. The shares were sold at an average price of $30.00, for a total transaction of $750,000.00. Following the transaction, the director directly owned 49,124 shares of the company’s stock, valued at $1,473,720. The trade was a 33.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 211,488 shares of company stock worth $5,072,884. 9.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on STOK. BTIG Research reiterated a “buy” rating and issued a $39.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, November 5th. Wedbush upped their target price on shares of Stoke Therapeutics from $22.00 to $32.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Stoke Therapeutics in a research note on Wednesday, November 19th. Canaccord Genuity Group lifted their price target on shares of Stoke Therapeutics from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Stoke Therapeutics from $15.00 to $25.00 and gave the stock a “neutral” rating in a report on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Stoke Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $31.00.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.